Dear Client,
2015 is fast approaching, so I am reaching out to about your upcoming strategic plans.
As the CEO of BioInformant, a research firm specializing in the stem cell sector, I have been observing that the trend of stem cell biobanking is becoming increasingly common among cord blood banks.
Cord blood banking is a specialized niche, so there are several key benefits to diversifying into related areas of stem cell storage, including increased revenue potential and diversification, with minimal risk and up-front investment.
I have recently suggested this strategic approach to several cord blood banks with whom I consult, as I believe this trend will continue among leading companies within the sector.
For this reason, I've recently partnered with American Cryostem, a U.S. based company who offers cord blood banks the opportunity to license their adipose tissue and adipose-derived stem cell processing and storage platform technologies, as well as marketing materials to allow for fast integration of these services.
Please note that the company will grant only one exclusive license per region, so it is best to respond quickly if you are interested in expanding your cord blood banking services to include adipose tissue and stem cell collection, processing, storage, expansion and differentiation services.
On your request, I will send you an:
1. Overview of the key benefits that American Cryostem offers to licensees
2. Introduction letter from the company American Cryostem
I look forward to assisting your profitability in 2015, through strategic options and informed market insights.
Best Wishes,
Cade Hildreth
--
Cade Hildreth, B.S., M.S.
President/CEO
BioInformant Worldwide, L.L.C.
Your Global Leader in Stem Cell Industry Data
U.S. Phone: (703) 859-7617
International Phone: (00-1) 703-859-7617
www.bioinformantworldwide.com
hildreth@bioinformant.com |
| |
